196 related articles for article (PubMed ID: 17827007)
41. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
42. Preparation of yuanhuacine and relative daphne diterpene esters from Daphne genkwa and structure-activity relationship of potent inhibitory activity against DNA topoisomerase I.
Zhang S; Li X; Zhang F; Yang P; Gao X; Song Q
Bioorg Med Chem; 2006 Jun; 14(11):3888-95. PubMed ID: 16488610
[TBL] [Abstract][Full Text] [Related]
43. Understanding topoisomerase I and II in terms of QSAR.
Verma RP
Bioorg Med Chem; 2005 Feb; 13(4):1059-67. PubMed ID: 15670914
[TBL] [Abstract][Full Text] [Related]
44. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2006 Dec; 49(26):7740-53. PubMed ID: 17181156
[TBL] [Abstract][Full Text] [Related]
45. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
46. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
47. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
[TBL] [Abstract][Full Text] [Related]
48. Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: influence on topoisomerase I-targeting activity and cytotoxicity.
Ruchelman AL; Kerrigan JE; Li TK; Zhou N; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 2004 Jul; 12(13):3731-42. PubMed ID: 15186859
[TBL] [Abstract][Full Text] [Related]
49. Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I.
Tesauro C; Fiorani P; D'Annessa I; Chillemi G; Turchi G; Desideri A
Biochem J; 2010 Jan; 425(3):531-9. PubMed ID: 19883377
[TBL] [Abstract][Full Text] [Related]
50. Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity.
Ruchelman AL; Zhu S; Zhou N; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem Lett; 2004 Nov; 14(22):5585-9. PubMed ID: 15482929
[TBL] [Abstract][Full Text] [Related]
51. Inhibitory activities against topoisomerase I and II by isoaurostatin derivatives and their structure-activity relationships.
Suzuki K; Okawara T; Higashijima T; Yokomizo K; Mizushima T; Otsuka M
Bioorg Med Chem Lett; 2005 Apr; 15(8):2065-8. PubMed ID: 15808469
[TBL] [Abstract][Full Text] [Related]
52. Effect of the anticancer drug oracin on mouse liver topoisomerases I and II.
Stuchlík S; Turna J; Miko M
J Pharm Pharmacol; 2005 May; 57(5):657-9. PubMed ID: 15901355
[TBL] [Abstract][Full Text] [Related]
53. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.
Morrell A; Placzek M; Parmley S; Grella B; Antony S; Pommier Y; Cushman M
J Med Chem; 2007 Sep; 50(18):4388-404. PubMed ID: 17676830
[TBL] [Abstract][Full Text] [Related]
54. C3-Spacer-containing circular oligonucleotides as inhibitors of human topoisomerase I.
Wang Y; Ng MT; Zhou T; Li X; Tan CH; Li T
Bioorg Med Chem Lett; 2008 Jun; 18(12):3597-602. PubMed ID: 18490159
[TBL] [Abstract][Full Text] [Related]
55. DNA topoisomerase I inhibitory alkaloids from Corydalis saxicola.
Cheng X; Wang D; Jiang L; Yang D
Chem Biodivers; 2008 Jul; 5(7):1335-44. PubMed ID: 18649321
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Nacro K; Zha CC; Guzzo PR; Jason Herr R; Peace D; Friedrich TD
Bioorg Med Chem; 2007 Jun; 15(12):4237-46. PubMed ID: 17418582
[TBL] [Abstract][Full Text] [Related]
57. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
[TBL] [Abstract][Full Text] [Related]
58. Intramolecular direct C-H arylation approach to fused purines. Synthesis of purino[8,9-f]phenanthridines and 5,6-dihydropurino[8,9-a]isoquinolines.
Cerna I; Pohl R; Klepetárová B; Hocek M
J Org Chem; 2010 Apr; 75(7):2302-8. PubMed ID: 20199094
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin.
Sunami S; Nishimura T; Nishimura I; Ito S; Arakawa H; Ohkubo M
J Med Chem; 2009 May; 52(10):3225-37. PubMed ID: 19397324
[TBL] [Abstract][Full Text] [Related]
60. Total and semisynthesis and in vitro studies of both enantiomers of 20-fluorocamptothecin.
Tangirala RS; Dixon R; Yang D; Ambrus A; Antony S; Agama K; Pommier Y; Curran DP
Bioorg Med Chem Lett; 2005 Nov; 15(21):4736-40. PubMed ID: 16140529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
